Logo image of GUD.CA

KNIGHT THERAPEUTICS INC (GUD.CA) Stock Fundamental Analysis

TSX:GUD - Toronto Stock Exchange - CA4990531069 - Common Stock - Currency: CAD

5.72  -0.03 (-0.52%)

Fundamental Rating

5

GUD gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 36 industry peers in the Pharmaceuticals industry. GUD is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. GUD is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

GUD had negative earnings in the past year.
GUD had a positive operating cash flow in the past year.
In multiple years GUD reported negative net income over the last 5 years.
Of the past 5 years GUD 4 years had a positive operating cash flow.
GUD.CA Yearly Net Income VS EBIT VS OCF VS FCFGUD.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50M -100M -150M

1.2 Ratios

Looking at the Return On Assets, with a value of -3.19%, GUD is in the better half of the industry, outperforming 78.79% of the companies in the same industry.
Looking at the Return On Equity, with a value of -3.97%, GUD belongs to the top of the industry, outperforming 84.85% of the companies in the same industry.
With a decent Return On Invested Capital value of 0.33%, GUD is doing good in the industry, outperforming 75.76% of the companies in the same industry.
Industry RankSector Rank
ROA -3.19%
ROE -3.97%
ROIC 0.33%
ROA(3y)-1.01%
ROA(5y)0.43%
ROE(3y)-1.34%
ROE(5y)0.51%
ROIC(3y)N/A
ROIC(5y)N/A
GUD.CA Yearly ROA, ROE, ROICGUD.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 2 -2 4

1.3 Margins

The Operating Margin of GUD (1.12%) is better than 75.76% of its industry peers.
GUD's Gross Margin of 48.26% is fine compared to the rest of the industry. GUD outperforms 60.61% of its industry peers.
In the last couple of years the Gross Margin of GUD has declined.
Industry RankSector Rank
OM 1.12%
PM (TTM) N/A
GM 48.26%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.33%
GM growth 5Y-10.81%
GUD.CA Yearly Profit, Operating, Gross MarginsGUD.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 1K 2K 3K

8

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so GUD is destroying value.
Compared to 1 year ago, GUD has less shares outstanding
Compared to 5 years ago, GUD has less shares outstanding
Compared to 1 year ago, GUD has an improved debt to assets ratio.
GUD.CA Yearly Shares OutstandingGUD.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M
GUD.CA Yearly Total Debt VS Total AssetsGUD.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M 1B

2.2 Solvency

GUD has an Altman-Z score of 2.77. This is not the best score and indicates that GUD is in the grey zone with still only limited risk for bankruptcy at the moment.
With an excellent Altman-Z score value of 2.77, GUD belongs to the best of the industry, outperforming 87.88% of the companies in the same industry.
GUD has a debt to FCF ratio of 2.82. This is a good value and a sign of high solvency as GUD would need 2.82 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 2.82, GUD belongs to the best of the industry, outperforming 84.85% of the companies in the same industry.
GUD has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
GUD has a better Debt to Equity ratio (0.05) than 72.73% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF 2.82
Altman-Z 2.77
ROIC/WACC0.04
WACC8.78%
GUD.CA Yearly LT Debt VS Equity VS FCFGUD.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M 400M 600M 800M 1B

2.3 Liquidity

GUD has a Current Ratio of 3.36. This indicates that GUD is financially healthy and has no problem in meeting its short term obligations.
GUD has a Current ratio of 3.36. This is amongst the best in the industry. GUD outperforms 87.88% of its industry peers.
GUD has a Quick Ratio of 2.39. This indicates that GUD is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 2.39, GUD belongs to the best of the industry, outperforming 87.88% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.36
Quick Ratio 2.39
GUD.CA Yearly Current Assets VS Current LiabilitesGUD.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

4

3. Growth

3.1 Past

GUD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -383.33%.
The Revenue has been growing slightly by 3.87% in the past year.
Measured over the past years, GUD shows a very strong growth in Revenue. The Revenue has been growing by 92.24% on average per year.
EPS 1Y (TTM)-383.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
Revenue 1Y (TTM)3.87%
Revenue growth 3Y18.05%
Revenue growth 5Y92.24%
Sales Q2Q%13.21%

3.2 Future

Based on estimates for the next years, GUD will show a very strong growth in Earnings Per Share. The EPS will grow by 37.10% on average per year.
GUD is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.34% yearly.
EPS Next Y68.44%
EPS Next 2Y58.67%
EPS Next 3Y40.23%
EPS Next 5Y37.1%
Revenue Next Year8.67%
Revenue Next 2Y3.98%
Revenue Next 3Y6.29%
Revenue Next 5Y7.34%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
GUD.CA Yearly Revenue VS EstimatesGUD.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M 500M
GUD.CA Yearly EPS VS EstimatesGUD.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.2 -0.2 0.4 0.6

5

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GUD. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 69.07 indicates a quite expensive valuation of GUD.
81.82% of the companies in the same industry are more expensive than GUD, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 94.77. GUD is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 69.07
GUD.CA Price Earnings VS Forward Price EarningsGUD.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, GUD is valued cheaply inside the industry as 90.91% of the companies are valued more expensively.
69.70% of the companies in the same industry are more expensive than GUD, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 27.8
EV/EBITDA 6.68
GUD.CA Per share dataGUD.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as GUD's earnings are expected to grow with 40.23% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y58.67%
EPS Next 3Y40.23%

0

5. Dividend

5.1 Amount

GUD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

KNIGHT THERAPEUTICS INC

TSX:GUD (2/7/2025, 7:00:00 PM)

5.72

-0.03 (-0.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)N/A N/A
Inst Owners12.58%
Inst Owner ChangeN/A
Ins Owners1.53%
Ins Owner ChangeN/A
Market Cap573.66M
Analysts80
Price Target7.23 (26.4%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-149.5%
Min EPS beat(2)-199.01%
Max EPS beat(2)-100%
EPS beat(4)0
Avg EPS beat(4)-539.47%
Min EPS beat(4)-1165.13%
Max EPS beat(4)-100%
EPS beat(8)3
Avg EPS beat(8)-201.35%
EPS beat(12)5
Avg EPS beat(12)-470.41%
EPS beat(16)8
Avg EPS beat(16)-295.5%
Revenue beat(2)2
Avg Revenue beat(2)5%
Min Revenue beat(2)2.55%
Max Revenue beat(2)7.46%
Revenue beat(4)3
Avg Revenue beat(4)2.3%
Min Revenue beat(4)-6.65%
Max Revenue beat(4)7.46%
Revenue beat(8)7
Avg Revenue beat(8)9.02%
Revenue beat(12)10
Avg Revenue beat(12)8.83%
Revenue beat(16)13
Avg Revenue beat(16)10.26%
PT rev (1m)0%
PT rev (3m)-4.25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-44.57%
EPS NY rev (1m)0%
EPS NY rev (3m)-733.33%
Revenue NQ rev (1m)-0.58%
Revenue NQ rev (3m)-3.89%
Revenue NY rev (1m)-0.05%
Revenue NY rev (3m)0.19%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 69.07
P/S 1.65
P/FCF 27.8
P/OCF 10.87
P/B 0.74
P/tB 1.4
EV/EBITDA 6.68
EPS(TTM)-0.29
EYN/A
EPS(NY)0.08
Fwd EY1.45%
FCF(TTM)0.21
FCFY3.6%
OCF(TTM)0.53
OCFY9.2%
SpS3.48
BVpS7.72
TBVpS4.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -3.19%
ROE -3.97%
ROCE 0.46%
ROIC 0.33%
ROICexc 0.42%
ROICexgc 0.91%
OM 1.12%
PM (TTM) N/A
GM 48.26%
FCFM 5.92%
ROA(3y)-1.01%
ROA(5y)0.43%
ROE(3y)-1.34%
ROE(5y)0.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.33%
GM growth 5Y-10.81%
F-Score6
Asset Turnover0.36
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF 2.82
Debt/EBITDA 0.67
Cap/Depr 63.48%
Cap/Sales 9.21%
Interest Coverage 0.42
Cash Conversion 96.81%
Profit Quality N/A
Current Ratio 3.36
Quick Ratio 2.39
Altman-Z 2.77
F-Score6
WACC8.78%
ROIC/WACC0.04
Cap/Depr(3y)176.29%
Cap/Depr(5y)132.48%
Cap/Sales(3y)34.63%
Cap/Sales(5y)24.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-383.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
EPS Next Y68.44%
EPS Next 2Y58.67%
EPS Next 3Y40.23%
EPS Next 5Y37.1%
Revenue 1Y (TTM)3.87%
Revenue growth 3Y18.05%
Revenue growth 5Y92.24%
Sales Q2Q%13.21%
Revenue Next Year8.67%
Revenue Next 2Y3.98%
Revenue Next 3Y6.29%
Revenue Next 5Y7.34%
EBIT growth 1Y244.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year2104.72%
EBIT Next 3Y189.74%
EBIT Next 5Y100.55%
FCF growth 1Y12.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.55%
OCF growth 3YN/A
OCF growth 5YN/A